Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Switzerland

 

Swiss labs suffer 10% cut, more may follow

Switzerland has chopped its diagnostic lab prices by 10% in a move that is billed as saving CHf 140m (€141). There could well be further crackdowns following a publication highlighting the massive differences between Swiss prices and those in France, Germany and the Netherlands.

Mediclinic rejects £3.4bn takeover bid from consortium led by largest shareholder

Multinational South African hospital group Mediclinic has rejected a proposal for a possible cash offer of £3.4bn for the company’s entire share capital. The proposal came from a consortium comprising Mediclinic’s current largest shareholder, South African investment holding firm Remgro, and Mediterranean Shipping Company (MSC), the world’s second largest container shipping provider.

Swiss imaging and lab groups sigh with relief

A new outpatient tariff which would have taken 6-10% points off imaging prices has been kicked down the road for the third time by the byzantine Swiss healthcare system. It would have severely clipped the very high margins enjoyed by many whilst upping prices for primary care.

Affidea deal – underbidders and EBITDA

HBI hears that the surprise buyer of European imaging and cancer treatment provider Affidea, Groupe Bruxelles Lambert (GBL) may not have been the highest bidder, despite winning out. HBI considers who else was in the running, and the EBITDA figure that may have been used for the deal.

Interview: Giuseppe Recchi, CEO, Affidea

In light of multinational diagnostic imaging provider Affidea's recent acquisition of Brust Zentrum, a Zurich-based breast cancer care provider, we speak to CEO Giuseppe Recchi about the company's vision to create a pan-European polydiagnostic outpatient platform.

Sanoptis sells to unexpected buyer

As predicted by HBI earlier this year, fast-growing German and Swiss ophthalmology group Sanoptis has sold - but to an unexpected buyer. Owner Telemos Capital has signed an agreement to sell to family-backed investment holding company Groupe Bruxelles Lambert (GBL), the same group which has also just agreed to buy a majority stake in European imaging and cancer treatment provider Affidea.

Affidea bought by Groupe Bruxelles Lambert

Groupe Bruxelles Lambert (“GBL”) has signed definitive agreements to acquire a majority stake in European imaging and cancer treatment provider Affidea from B-FLEXION, the private investment firm of the Switzerland-based billionaire Bertarelli family. GBL will invest up to €1bn of equity for the transaction which is its first substantive healthcare investment.

Mediclinic returns to growth in FY22

A strong performance at home saw South African hospital group Mediclinic's revenue grow 8% in the financial year ending March 31, 2022 and its EBITDA margin move up two percentage points to 16%.

Atrys: What’s the focus?

No listed health care group in Europe has grown anything like as fast as Atrys Health, which now spans Spain, Portugal, Switzerland and four Latin American countries. But does its M&A strategy have any coherence? We talk to Atrys CFO Josep Maria Huch.

Find Us